Wright-Mitchell Jane 4

What Happened Jane Wright-Mitchell, Chief Legal Officer of Vera Therapeutics (VERA), received two awards on March 23, 2026: 42,403 restricted stock units (RSUs) and 56,850 derivative shares (stock-option style award), each reported at $0 per share. These were grants under the issuer’s compensation/inducement program rather than open-market purchases or sales.

Key Details

• Transaction date: March 23, 2026. Form 4 filed March 25, 2026 (timely filing).
• Consideration: $0.00 per share for both the 42,403 RSUs and the 56,850 derivative award.
• Shares owned after transaction: Not specified in the filing.
• Footnote F1 (RSUs): 42,403 RSUs granted under the Issuer’s 2024 Inducement Plan. Vesting: one-fourth (rounded) vests on each of May 20, 2027, 2028, 2029 and 2030, subject to continuous service.
• Footnote F2 (derivative/option): 56,850-share derivative award vests 12/48ths on March 23, 2027, then 1/48th monthly thereafter, subject to continuous service.
• Nature of transaction code: A = Award/Grant. No sale or purchase reported; no tax-withholding or disposition shown.

Context These awards are compensation-related grants that vest over multiple years and do not reflect an immediate cash purchase or sale. The derivative entry represents a stock-option–style award with a multi-year vesting schedule; such grants typically align executive incentive/retention rather than indicate near-term trading intent.